Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium

Location: Online or In-Person
Start Date: January 21st, 0021
End Date: July 21st, 0022

The primary aim of this study is to evaluate the effect of a liquid form of leucovorin calcium on language impairments in very young children with ASD. Leucovorin calcium is a compound similar to folic acid a necessary vitamin. The study is a 24-week 2-phase study, which means that all participants receive the study treatment in the open-label phase. Visit https://clinicaltrials.gov/ct2/show/NCT04060017

Eligibility Criteria
2.5-5 year old children with an autism diagnosis currently receiving some amount of ABA therapy per week.

Contact Information
Email daniel.mishan@downstate.edu or call the Child Development Clinic at Downstate 718-270-2272